Processa Pharmaceuticals Inc - at Highest Ngc-Cap Dose, All Three Evaluable Patients Had Pfs With Two Partial Responses (Pr) and One Stable Disease
在最高Ngc-Cap劑量下,所有三個可評估患者均有PFS,其中兩者爲部分反應(PR),一者爲穩定疾病。
Processa Pharmaceuticals Inc - at Highest Ngc-Cap Dose, All Three Evaluable Patients Had Pfs With Two Partial Responses (Pr) and One Stable Disease
在最高Ngc-Cap劑量下,所有三個可評估患者均有PFS,其中兩者爲部分反應(PR),一者爲穩定疾病。
譯文內容由第三人軟體翻譯。